⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3226475 | 0.74 | — | — | |
| SCHEMBL8932212 | 0.70 | — | — | |
| SCHEMBL422869 | 0.70 | — | — | |
| SCHEMBL4191579 | 0.69 | — | — | |
| SCHEMBL2197713 | 0.68 | — | — | |
| SCHEMBL2197710 | 0.68 | — | — | |
| SCHEMBL18665213 | 0.67 | — | — | |
| SCHEMBL7830505 | 0.67 | — | — | |
| SCHEMBL20768164 | 0.67 | ALDH1A1 (0.35) | — | |
| SCHEMBL7830503 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078082-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260069549-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX INC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4186888-B1 | COMPOUND AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX INC (US) | 2025-11-26 | — | — | EP | disclosed |
| US-12404232-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250228777-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2025-07-17 | — | — | US | disclosed |
| US-12324859-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX, INC. (US) | 2025-06-10 | — | — | US | disclosed |
| US-12263248-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-12151995-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| EP-4286012-A2 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ModernaTX, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| EP-3736261-B1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX INC (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-4186888-A1 | COMPOUND AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ModernaTX, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20220409536-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2022-12-29 | — | — | US | disclosed |
| US-20220380299-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2022-12-01 | — | — | US | disclosed |
| EP-3596041-B1 | COMPOUND AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX INC (US) | 2022-11-02 | — | — | EP | disclosed |
| US-20210154148-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2021-05-27 | — | — | US | disclosed |
| US-10857105-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | MordernaTX, Inc. (US) | 2020-12-08 | — | — | US | disclosed |
| US-20190314292-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2019-10-17 | — | — | US | disclosed |